# A Study To Assess Single Dosage Strength Of GW685698/GW642444 Chronic Obstructive Pulmonary Disease (COPD)

> **NCT00731822** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 60 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** GW685698/GW642444

## Key facts

- **NCT ID:** NCT00731822
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2016-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00731822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00731822, "A Study To Assess Single Dosage Strength Of GW685698/GW642444 Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00731822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*